menu

CME: Specialty Provider Insights on Evolving Paradigms in COPD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Specialty Provider Insights on Evolving Paradigms in COPD

close
1.25 credits
1 Hour 15 Minutes
Specialty Provider Insights on Evolving Paradigms in COPD
RestartResume
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
Details
Presenters
Comments
  • Overview

    Despite updated recommendations, there is limited practical guidance on individualizing therapy or identifying patients with chronic obstructive pulmonary disease (COPD) who may benefit from treatment escalation. In addition, lack of knowledge of appropriate COPD inhaler use and self-management strategies persist among patients and caregivers, precluding optimal therapeutic benefit and clinical outcomes.

    That’s why this replay of a live broadcast features 3 international experts in COPD who review and discuss the clinical science behind dual-bronchodilation therapy, advances in triple therapy, and the new COPD recommendations, as well as implementation of practical individualized treatment and inhaler strategies for patients with COPD.

  • Target Audience

    This educational initiative is designed for pulmonology, critical care/intensive care, and other specialty physicians, physician assistants, nurse practitioners, and nurses who manage patients with COPD.

  • Learning Objectives

    • Explain key clinical findings and related initial and escalation therapy clinical guidelines, regarding dual bronchodilation and ICS-containing inhalation maintenance therapy for COPD.
    • Propose strategies to recognize exacerbations in COPD and optimize escalation therapy to address disease burden.
    • Identify tactics to provide COPD-specific patient education and inhaler training.
    • Develop appropriate inhaled maintenance treatment strategies based on patient symptoms, exacerbation risks, inhaler device, and clinical guidelines.
  • Continuing Education Information

    JOINT ACCREDITATION STATEMENT – In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and ASiM CE, LLC.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Physician Continuing Medical Education – The Postgraduate Institute for Medicine  designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Disclosure of Conflicts of Interest

    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

    The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

    Name of Faculty or Presenter 
    James F. Donohue, MD                                          
    Reports receiving consulting fees from AstraZeneca, GlaxoSmithKline, Mylan, Sunovion Pharmaceuticals Inc, and Theravance Biopharma; and receiving fees for non-CME/CE services from GlaxoSmithKline, Mylan, and Theravance Biopharma.

    MeiLan K. Han, MD                                                  
    Reports receiving royalties from UpToDate.com; receiving consulting fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, and Mylan; and receiving research support from Novartis and Sunovion.

    Nicola A. Hanania, MD, MS                                    
    Reports receiving consulting fees from AstraZeneca, Genentech Inc, GlaxoSmithKline, Novartis, Regeneron Pharmaceuticals Inc, and Sanofi Genzyme; and reports performing contracted research for AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Gossamer Bio, Novartis, and Sanofi Genzyme.

    Planners and Managers – The PIM planners and managers have nothing to disclose.
    The following ASiM CE, LLC planners and managers, Jessica Marshall, PhD, and Jessica Epps, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

     

  • Method of Participation and Request for Credit

    There are no fees for participating and receiving CME credit for this activity. During the period November 25th, 2019 through November 25th, 2020, participants must read the learning objectives and faculty disclosures and study the educational activity. 

    If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation on ReachMD.com. Upon registering and successfully completing the post-test with a score of 75% or better and the activity evaluation, your certificate will be made available immediately. 

     
  • Disclosure of Unlabeled Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Commercial Support

    This educational activity is supported by an independent educational grant from GlaxoSmithKline.

  • Provider(s)/Educational Partner(s)

     

    Jointly provided by Postgraduate Institute for Medicine and ASiM.

  • Media

    Internet

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Despite updated recommendations, there is limited practical guidance on individualizing therapy or identifying patients with chronic obstructive pulmonary disease (COPD) who may benefit from treatment escalation. In addition, lack of knowledge of appropriate COPD inhaler use and self-management strategies persist among patients and caregivers, precluding optimal therapeutic benefit and clinical outcomes.

    That’s why this replay of a live broadcast features 3 international experts in COPD who review and discuss the clinical science behind dual-bronchodilation therapy, advances in triple therapy, and the new COPD recommendations, as well as implementation of practical individualized treatment and inhaler strategies for patients with COPD.

  • Target Audience

    This educational initiative is designed for pulmonology, critical care/intensive care, and other specialty physicians, physician assistants, nurse practitioners, and nurses who manage patients with COPD.

  • Learning Objectives

    • Explain key clinical findings and related initial and escalation therapy clinical guidelines, regarding dual bronchodilation and ICS-containing inhalation maintenance therapy for COPD.
    • Propose strategies to recognize exacerbations in COPD and optimize escalation therapy to address disease burden.
    • Identify tactics to provide COPD-specific patient education and inhaler training.
    • Develop appropriate inhaled maintenance treatment strategies based on patient symptoms, exacerbation risks, inhaler device, and clinical guidelines.
  • Continuing Education Information

    JOINT ACCREDITATION STATEMENT – In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and ASiM CE, LLC.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Physician Continuing Medical Education – The Postgraduate Institute for Medicine  designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Disclosure of Conflicts of Interest

    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

    The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

    Name of Faculty or Presenter 
    James F. Donohue, MD                                          
    Reports receiving consulting fees from AstraZeneca, GlaxoSmithKline, Mylan, Sunovion Pharmaceuticals Inc, and Theravance Biopharma; and receiving fees for non-CME/CE services from GlaxoSmithKline, Mylan, and Theravance Biopharma.

    MeiLan K. Han, MD                                                  
    Reports receiving royalties from UpToDate.com; receiving consulting fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, and Mylan; and receiving research support from Novartis and Sunovion.

    Nicola A. Hanania, MD, MS                                    
    Reports receiving consulting fees from AstraZeneca, Genentech Inc, GlaxoSmithKline, Novartis, Regeneron Pharmaceuticals Inc, and Sanofi Genzyme; and reports performing contracted research for AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Gossamer Bio, Novartis, and Sanofi Genzyme.

    Planners and Managers – The PIM planners and managers have nothing to disclose.
    The following ASiM CE, LLC planners and managers, Jessica Marshall, PhD, and Jessica Epps, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

     

  • Method of Participation and Request for Credit

    There are no fees for participating and receiving CME credit for this activity. During the period November 25th, 2019 through November 25th, 2020, participants must read the learning objectives and faculty disclosures and study the educational activity. 

    If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation on ReachMD.com. Upon registering and successfully completing the post-test with a score of 75% or better and the activity evaluation, your certificate will be made available immediately. 

     
  • Disclosure of Unlabeled Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Commercial Support

    This educational activity is supported by an independent educational grant from GlaxoSmithKline.

  • Provider(s)/Educational Partner(s)

     

    Jointly provided by Postgraduate Institute for Medicine and ASiM.

  • Media

    Internet

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 1/25/20